News | Cardiac Imaging | March 13, 2018

AutoPlaque technology will accelerate HeartFlow’s efforts to bring plaque assessment to the HeartFlow Analysis

HeartFlow Enters into Licensing Agreement with Cedars-Sinai for Coronary Plaque Assessment Technology

March 13, 2018 –  HeartFlow, Inc. today announced that it has entered into a licensing and technology transfer agreement with Cedars-Sinai in Los Angeles for AutoPlaque technology, a software tool used to detect and characterize coronary artery plaque based on coronary computed tomography angiography (CCTA) images. HeartFlow plans to use the AutoPlaque technology in its efforts to provide plaque assessment in future products, providing physicians with more information to help diagnose patients with coronary artery disease (CAD) and determine optimal treatment pathways.

The assessment of vulnerable plaque – lesions in coronary arteries that have the potential to rupture and cause acute coronary syndrome (ACS) – is an important area of clinical research. Results of the EMERALD (Exploring the MEchanism of the plaque Rupture in Acute coronary syndrome using coronary CT angiography and computationaL fluidDynamics) study, which were presented at EuroPCR 2016, demonstrated that the HeartFlow® FFRct Analysis, together with an assessment of coronary plaque, may help predict which coronary plaques are most likely to rupture. The HeartFlow FFRct Analysis is a first-of-its-kind non-invasive technology that provides a personalized 3D model of the heart to help clinicians diagnose and treat patients with suspected coronary artery disease (CAD).

“In addition to assessing lesion-specific physiology, understanding and characterizing coronary artery plaque is important in determining the most appropriate treatment path for patients with suspected CAD. The power of utilizing the AutoPlaque tool in the HeartFlow Analysis may accelerate our ability to analyze and characterize plaque in coronary arteries,” said John H. Stevens, M.D., president and chief executive officer, HeartFlow.

CAD, which today affects 16.8 million Americans, develops when the coronary arteries narrow, reducing blood flow to the heart and causing angina (chest pain), myocardial infarction (heart attack) and death. Acute Coronary Syndrome (ACS) is a life-threatening condition that occurs due to decreased blood flow to the heart, often because of a sudden rupture of plaque inside a coronary artery. ACS encompasses both unstable angina and myocardial infarction. In the United States, an ACS occurs every 25 seconds and someone dies from an ACS-related event every minute. Each year, approximately 1.4 million Americans are hospitalized with ACS, of whom 810,000 are hospitalized for myocardial infarction. Studies have shown that plaque rupture causes approximately 75 percent of fatal myocardial infarctions.

About the HeartFlow FFRct Analysis

Clinicians diagnostics someone with suspected CAD want to know as definitively as possible if the individual has a significant blockage in their coronary arteries. They also want to know the impact of that blockage on blood flow so they can best determine which treatment pathway is appropriate (e.g., medical management, stenting or coronary artery bypass grafting).

Data from a patient’s non-invasive CCTA are securely uploaded from the hospital’s system to the cloud. HeartFlow leverages deep learning to create a personalized, digital 3D model of the patient’s coronary arteries. The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and assess the impact of blockages on coronary blood flow. The HeartFlow FFRct Analysis is provided via a secure online interface to offer actionable information to enable clinicians to determine the optimal course of treatment. To date, clinicians around the world have used the HeartFlow Analysis for more than 15,000 patients to aid in the diagnosis of heart disease.

This technology has been demonstrated to reduce unnecessary and invasive diagnostic coronary angiography procedures, which can be associated with bleeding, stroke, major blood vessel damage and other serious complications. It also significantly reduces healthcare costs for hospitals.

For more information: www.heartflow.com


Related Content

News | Computed Tomography (CT)

January 30, 2023 — Photon-counting detector CT reduces the amount of contrast needed for CT angiography (CTA) while ...

Time January 30, 2023
arrow
News | Radiology Imaging

January 23, 2023 — Canon Medical Systems has released a new eBook featuring its new medical imaging roadshow. This new ...

Time January 23, 2023
arrow
Videos | Cardiac Imaging

Artificial intelligence and general consolidation were two top cardiology trends at RSNA22. ITN/DAIC spoke with Val ...

Time January 23, 2023
arrow
News | Artificial Intelligence

January 20, 2023 — Artificial intelligence (AI) can reconstruct coarsely-sampled, rapid magnetic resonance imaging (MRI) ...

Time January 20, 2023
arrow
News | RSNA

January 18, 2023 — Artificial intelligence (AI) may help improve care for patients who show up at the hospital with ...

Time January 18, 2023
arrow
News | Radiology Business

January 18, 2023 — Addressing the growing demand for medical imaging and a shortage of radiologists, Bayer announced the ...

Time January 18, 2023
arrow
Feature | Cardiac Imaging | By Christine Book

According to the U.S. Centers for Disease Control and Prevention (CDC), one person dies every 37 seconds in the United ...

Time January 18, 2023
arrow
Feature | RSNA | By Melinda Taschetta-Millane

The Radiological Society of North America’s (RSNA) 108th Scientific Assembly and Annual Meeting (RSNA22) took place at ...

Time January 16, 2023
arrow
News | Cardiac Imaging

January 13, 2023 — Nuclear stress testing performed with single-photon emission computed tomography (SPECT) is the most ...

Time January 13, 2023
arrow
News | Radiology Business

January 12, 2023 — GE HealthCare announced it has entered into an agreement to acquire IMACTIS, an innovator in the ...

Time January 12, 2023
arrow
Subscribe Now